'Molecular assassin' targets disease gene ( University of New South Wales (UNSW) re...)

'Molecular assassin' targets disease gene

University of New South Wales (UNSW) researchers have announced they are developing a new class of experimental drug that has the potential to treat a diverse range of health problems, from inflammation and cancer through to eye and heart disease. The research is published in the July issue of Nature Biotechnology.

Certain types of skin cancers and blindness due to age-related macular degeneration (AMD) and diabetic retinopathy are likely to be among the first uses for the drug. AMD is the most common cause of blindness in Australia (Macular Degeneration Foundation).

The experimental drug has already been shown to be effective on skin cancers in pre-clinical models, in another paper published this month by Professor Khachigian's team in the journal, Oncogene.

"This may be a 'one-size fits all' therapy, because it targets a master regulator gene called c-Jun which appears to be involved in all of these diseases," said UNSW Professor Levon Khachigian, of the Centre for Vascular Research (CVR), who is the senior author of the Nature Biotechnology paper.

"c-Jun is an important disease-causing gene," said Professor Khachigian, a molecular biologist. "It stands out because we don't see much of it in normal tissue but it is highly expressed in diseased blood vessels, eyes, lungs, joints, and in the gut ?in any number of areas involving inflammation and aggressive vascular growth.

"Our experimental drug, Dz13, is like a secret agent that finds its target, c-Jun, within the cell and destroys it," he said. "It is a specific, pre-programmed 'molecular assassin'."

The paper in Nature Biotechnology shows the potential of c-Jun as a drug target in inflammation. It details tests in a variety of pre-clinical models showing how effective Dz13 is in problems such as eye disease and arthritis.

The next phase in the therapy's development would be a trial, involving up to 10 people with non-melanoma skin cancers. The tumours woul
'"/>

Source:University of New South Wales

Page: 1 2
Related biology news :

1. A bacterial genome reveals new targets to combat infectious disease
2. Study reveals candidate targets for anti-retroviral therapeutics
3. Smart drug targets deadly brain cancer
4. NHGRI targets 12 more organisms for genome sequencing
5. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
6. Novel targets found for the development of drugs to complement, or replace, statins
7. Vaccine targets tumors where they live
8. Study findings offer potential new targets for antibiotics
9. Switching to new anti-bacterial targets: Riboswitches
10. NHGRI announces new sequencing targets
11. NHGRI announces latest sequencing targets

Post Your Comments:

( University of New South Wales (UNSW) re...)'Molecular assassin' targets disease gene